{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Pamiparib", "query": { "intervention": "Pamiparib" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 11, "total_pages": 2, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Pamiparib&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-02T10:38:26.928Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02660034", "title": "The Safety, Pharmacokinetics and Antitumor Activity of BGB-A317 in Combination With BGB-290 in Participants With Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumors" ], "interventions": [ { "name": "Tislelizumab", "type": "BIOLOGICAL" }, { "name": "Pamiparib", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "BeiGene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 229, "start_date": "2016-02-02", "completion_date": "2020-09-09", "has_results": true, "last_update_posted_date": "2021-12-06", "last_synced_at": "2026-09-02T10:38:26.928Z", "location_count": 12, "location_summary": "Scottsdale, Arizona • Los Angeles, California • Denver, Colorado + 8 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Miami Beach", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02660034" }, { "nct_id": "NCT03150810", "title": "Study to Assess Safety, Tolerability and Clinical Activity of BGB-290 in Combination With Temozolomide (TMZ) in Participants With Locally Advanced or Metastatic Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Locally Advanced or Metastatic Solid Tumors" ], "interventions": [ { "name": "Pamiparib", "type": "DRUG" }, { "name": "Temozolomide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "BeiGene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 139, "start_date": "2017-06-28", "completion_date": "2023-05-04", "has_results": true, "last_update_posted_date": "2024-12-20", "last_synced_at": "2026-09-02T10:38:26.928Z", "location_count": 7, "location_summary": "Grand Rapids, Michigan • St Louis, Missouri • New York, New York + 4 more", "locations": [ { "city": "Grand Rapids", "state": "Michigan" }, { "city": "St Louis", "state": "Missouri" }, { "city": "New York", "state": "New York" }, { "city": "The Bronx", "state": "New York" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT03150810" }, { "nct_id": "NCT05526924", "title": "Dosing Study of Radiation Combined With Tislelizumab and Pamiparib in Patients With Previously Treated Head and Neck Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Head and Neck Cancer", "Head and Neck Squamous Cell Carcinoma", "Head and Neck Carcinoma", "Head and Neck Cancer Stage IV", "Head and Neck Cancers - Throat" ], "interventions": [ { "name": "Chemoradiation", "type": "RADIATION" }, { "name": "Pamiparib", "type": "DRUG" }, { "name": "Hydroxyurea", "type": "DRUG" }, { "name": "Fluorouracil (5FU)", "type": "DRUG" }, { "name": "Tislelizumab", "type": "DRUG" } ], "intervention_types": [ "RADIATION", "DRUG" ], "sponsor": "University of Chicago", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2023-03-07", "completion_date": "2028-01-01", "has_results": false, "last_update_posted_date": "2026-03-04", "last_synced_at": "2026-09-02T10:38:26.928Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT05526924" }, { "nct_id": "NCT03712930", "title": "Treatment of Metastatic Castration-Resistant Prostate Cancer With Homologous Recombination Deficiency", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Castration-Resistant Prostate Cancer (mCRPC)", "Homologous Recombination Deficiency (HRD)" ], "interventions": [ { "name": "Pamiparib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "BeiGene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 13, "start_date": "2019-02-05", "completion_date": "2020-09-02", "has_results": true, "last_update_posted_date": "2021-11-17", "last_synced_at": "2026-09-02T10:38:26.928Z", "location_count": 3, "location_summary": "Athens, Georgia • The Bronx, New York • Seattle, Washington", "locations": [ { "city": "Athens", "state": "Georgia" }, { "city": "The Bronx", "state": "New York" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT03712930" }, { "nct_id": "NCT04164199", "title": "Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Advanced Malignancies" ], "interventions": [ { "name": "Tislelizumab", "type": "DRUG" }, { "name": "Pamiparib", "type": "DRUG" }, { "name": "Temozolomide", "type": "DRUG" }, { "name": "Sitravatinib", "type": "DRUG" }, { "name": "Ociperlimab", "type": "DRUG" }, { "name": "BAT1706", "type": "DRUG" }, { "name": "Fruquintinib", "type": "DRUG" }, { "name": "BGB-15025", "type": "DRUG" }, { "name": "Zanidatamab", "type": "DRUG" }, { "name": "BGB-A445", "type": "DRUG" }, { "name": "Surzebiclimab", "type": "DRUG" }, { "name": "Lenvatinib", "type": "DRUG" }, { "name": "LBL-007", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "BeOne Medicines", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 404, "start_date": "2019-12-19", "completion_date": "2026-05-23", "has_results": false, "last_update_posted_date": "2026-06-03", "last_synced_at": "2026-09-02T10:38:26.928Z", "location_count": 4, "location_summary": "Miami, Florida • New York, New York • Nashville, Tennessee + 1 more", "locations": [ { "city": "Miami", "state": "Florida" }, { "city": "New York", "state": "New York" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04164199" }, { "nct_id": "NCT03914742", "title": "BGB-290 and Temozolomide in Treating Patients With Recurrent Gliomas With IDH1/2 Mutations", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "IDH1 Mutation", "IDH2 Mutation", "Recurrent Glioblastoma", "Recurrent WHO Grade II Glioma", "Recurrent WHO Grade III Glioma" ], "interventions": [ { "name": "PARP Inhibitor BGB-290", "type": "DRUG" }, { "name": "Temozolomide", "type": "DRUG" }, { "name": "Therapeutic Conventional Surgery", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 67, "start_date": "2020-02-16", "completion_date": "2023-10-31", "has_results": true, "last_update_posted_date": "2025-01-14", "last_synced_at": "2026-09-02T10:38:26.928Z", "location_count": 12, "location_summary": "Birmingham, Alabama • Los Angeles, California • New Haven, Connecticut + 9 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT03914742" }, { "nct_id": "NCT03749187", "title": "BGB-290 and Temozolomide in Treating Isocitrate Dehydrogenase (IDH)1/2-Mutant Grade I-IV Gliomas", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Glioblastoma", "IDH1 Gene Mutation", "IDH2 Gene Mutation", "Low Grade Glioma", "Malignant Glioma", "Recurrent Glioblastoma", "Recurrent WHO Grade II Glioma", "Recurrent WHO Grade III Glioma", "WHO Grade II Glioma", "WHO Grade III Glioma" ], "interventions": [ { "name": "PARP Inhibitor BGB-290", "type": "DRUG" }, { "name": "Temozolomide (TMZ)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of California, San Francisco", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "13 Years", "maximum_age": "39 Years", "sex": "ALL", "summary": "13 Years to 39 Years" }, "enrollment_count": 78, "start_date": "2019-04-03", "completion_date": "2029-07-30", "has_results": false, "last_update_posted_date": "2026-03-13", "last_synced_at": "2026-09-02T10:38:26.928Z", "location_count": 11, "location_summary": "Los Angeles, California • San Francisco, California • New Haven, Connecticut + 8 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT03749187" }, { "nct_id": "NCT05038839", "title": "Cabozantinib and Pamiparib for the Treatment of Advanced of Refractory Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Malignant Solid Neoplasm", "Refractory Malignant Solid Neoplasm" ], "interventions": [ { "name": "Cabozantinib", "type": "DRUG" }, { "name": "Pamiparib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 44, "start_date": "2022-02-09", "completion_date": "2026-05-05", "has_results": false, "last_update_posted_date": "2026-05-12", "last_synced_at": "2026-09-02T10:38:26.928Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05038839" }, { "nct_id": "NCT04614909", "title": "Study of Pamiparib in Newly Diagnosed and rGBM", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Glioblastoma", "Glioblastoma Multiforme", "Glioblastoma Multiforme, Adult" ], "interventions": [ { "name": "Pamiparib", "type": "DRUG" }, { "name": "Olaparib", "type": "DRUG" }, { "name": "Radiation therapy", "type": "RADIATION" }, { "name": "Temozolomide", "type": "DRUG" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Nader Sanai", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 50, "start_date": "2021-01-11", "completion_date": "2025-05-28", "has_results": false, "last_update_posted_date": "2026-05-14", "last_synced_at": "2026-09-02T10:38:26.928Z", "location_count": 1, "location_summary": "Phoenix, Arizona", "locations": [ { "city": "Phoenix", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT04614909" }, { "nct_id": "NCT03427814", "title": "Study of BGB-290 or Placebo in Participants With Advanced or Inoperable Gastric Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Advanced or Inoperable Gastric Cancer" ], "interventions": [ { "name": "Pamiparib", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "BeiGene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 136, "start_date": "2018-07-03", "completion_date": "2023-01-03", "has_results": true, "last_update_posted_date": "2024-10-26", "last_synced_at": "2026-09-02T10:38:26.928Z", "location_count": 7, "location_summary": "Miami, Florida • West Palm Beach, Florida • Goshen, Indiana + 4 more", "locations": [ { "city": "Miami", "state": "Florida" }, { "city": "West Palm Beach", "state": "Florida" }, { "city": "Goshen", "state": "Indiana" }, { "city": "Wichita", "state": "Kansas" }, { "city": "Louisville", "state": "Kentucky" } ], "official_url": "https://clinicaltrials.gov/study/NCT03427814" } ] }